An important part of managing pulmonary arterial hypertension is working with a specialist who understands this rare and ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...
Jade Biosciences is a pre-revenue biotech focused on JADE101 for IgA nephropathy, offering potential. Read why I rate JBIO ...
A University of Alberta research team has found a genetic variant that can be used to identify which patients with pulmonary arterial hypertension need the most urgent care. "This could potentially ...
Onlymyhealth on MSN
What Is a Cardiac Shunt? Exploring Its Types, Symptoms, Causes, Diagnosis, And Treatment Options
The human heart is similar to a pump that maintains the circulation of oxygenated blood in the body. But sometimes, due to ...
Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...
A University of Alberta research team has found a genetic variant that can be used to identify which patients with pulmonary arterial hypertension ...
23d
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify ...
Cautionary Language Concerning Forward-Looking Statements ...
Charting, Price Performance, News & Related Contracts.
Scientists have created a new "molecular map" uncovering how an important human receptor involved in blood clotting and ...
Charting, Price Performance, News & Related Contracts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results